Science · Open for opinions
Will the FDA or Anvisa authorize human clinical trials for epigenetic editing against hepatitis B by October 31, 2026?
Evaluates the regulatory progress of the gene silencing technique between 09/23 and 10/31/2026. 57 opinions, 75% No
- Yes — 25%
- No — 75%
Deadline: October 31, 2026 at 11:59 PM UTC · 57 opinions
Resolution rules
Evaluates the regulatory progress of the gene silencing technique between 09/23 and 10/31/2026.
Source: www.nature.com
Frequently asked questions about this event
How is this event resolved?
Janela de apuração: de 23/09/2026 (00:00, horário de Brasília) até 31/10/2026 (23:59). Fatos, anúncios ou eventos anteriores ao início da janela não contam. Resolve como 'Sim' se a FDA ou a Anvisa aprovarem formalmente o início de ensaios clínicos em humanos para terapia de edição epigenética contra o vírus da hepatite B até 31/10/2026, conforme base oficial da FDA ou Diário Oficial da União. Caso contrário, resolve como 'Não'.
How are points scored?
Points depend on the share of votes your side had when you gave your opinion. Being right earns 100 minus that share. Being wrong costs that share.
Right now No has 75% of the votes: an opinion on it that turns out right earns about 25 points, a wrong one costs about 75.